U-Act-Early试验后3年随访:初始托珠单抗和/或甲氨蝶呤策略的长期有效性与安全性
U-Act-Early试验显示,在DMARD初治早期RA患者中,初始托珠单抗联合或不联合甲氨蝶呤策略在短期优于初始甲氨蝶呤策略。本研究对226/317例患者进行3年随访,发现5年内各组平均DAS28相似,99%患者至少一次达到持续缓解,仅30%患者出现影像学进展,组间无显著差异。
要点
- U-Act-Early试验后3年随访中,初始托珠单抗策略与初始甲氨蝶呤策略的长期临床结局差异消失。
- 5年内平均DAS28组间相似(P > 0.20),99%患者至少一次达到持续缓解。
- 仅30%患者5年内出现任何影像学进展,组间无显著差异。
核心结论
- 尽管短期初始托珠单抗策略临床获益最大,但长期重要临床结局差异消失,可能因继续贯彻达标治疗原则。
研究设计与样本
- U-Act-Early为2年随机安慰剂对照双盲试验,DMARD初治早期RA患者按策略初始托珠单抗(联合或不联合甲氨蝶呤)或甲氨蝶呤治疗至持续缓解。
- 试验结束后患者进入3年随访(PTFU),按标准治疗,第一年每3个月、之后每6个月收集数据。
- 317例起始患者中226例(71%)参与PTFU,采用混合效应模型比较初始策略组间有效性并校正混杂因素。
主要发现
- 5年总平均DAS28组间相似(P > 0.20)。
- U-Act-Early期间生物DMARD使用在初始托珠单抗组减少、初始甲氨蝶呤组增加,但随访期间该趋势未持续。
- 99%患者至少一次达到持续缓解。
- 226例患者中仅30%在5年内出现任何影像学进展,组间无显著差异。
关键数值与推荐
- 主要终点为随时间变化的DAS28。
- 持续缓解定义为至少一次达到持续缓解。
- 影像学进展定义为5年内出现任何影像学进展。
临床怎么用
- 初始托珠单抗策略的短期优势在长期随访中未能维持,支持以达标治疗原则指导后续治疗调整。
- 长期影像学进展比例较低,提示早期达标治疗可能带来较好的结构保护。
局限性
- 随访期间按标准治疗,非随机比较,可能存在混杂因素。
- 仅71%起始患者参与随访,存在失访偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: U-Act-Early was a 2-year, randomized placebo controlled, double-blind trial, in which DMARD-naïve early RA patients were treated to the target of sustained remission (SR). Two strategies initiating tocilizumab (TCZ), with and without methotrexate (MTX), were more effective than a strategy initiating MTX. The aim of the current study was to determine longer-term effectiveness in daily clinical practice. METHODS: At the end of U-Act-Early, patients were included in a 3-year post-trial follow-up (PTFU), in which treatment was according to standard care and data were collected every 3 months during the first year and every 6 months thereafter. Primary end point was disease activity score assessing 28 joints (DAS28) over time. Mixed effects models were used to compare effectiveness between initial strategy groups, correcting for relevant confounders. Between the groups as randomized, proportions of patients were tested for DMARD use, SR and radiographic progression of joint damage. RESULTS: Of patients starting U-Act-Early, 226/317 (71%) participated in the PTFU. Over the total 5 years, mean DAS28 was similar between groups (P > 0.20). During U-Act-Early, biologic DMARD use decreased in both TCZ initiation groups and increased in the MTX initiation group, but during follow-up this trend did not continue. SR was achieved at least once in 99% of patients. Of the 226 patients, only 30% had any radiographic progression over 5 years, without significant differences between the groups. CONCLUSION: Although in the short-term the strategies initiating TCZ yielded the most clinical benefit, in the longer-term differences in important clinical outcomes between the strategies disappeared, probably due to continuation of the treat-to-target principle.
引用
- Verhoeven MMA, Tekstra J, Welsing PMJ, et al. Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate. Rheumatology (Oxford). 2020. PMID: 31859346. doi:10.1093/rheumatology/kez602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。